Titre : Famille-26 de cytochromes P450

Famille-26 de cytochromes P450 : Questions médicales fréquentes

Termes MeSH sélectionnés :

Attention Deficit and Disruptive Behavior Disorders
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Famille-26 de cytochromes P450 : Questions médicales les plus fréquentes", "headline": "Famille-26 de cytochromes P450 : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Famille-26 de cytochromes P450 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-01-04", "dateModified": "2025-03-29", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Famille-26 de cytochromes P450" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Cytochrome P-450 enzyme system", "url": "https://questionsmedicales.fr/mesh/D003577", "about": { "@type": "MedicalCondition", "name": "Cytochrome P-450 enzyme system", "code": { "@type": "MedicalCode", "code": "D003577", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.422.220.453" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Retinoic acid 4-hydroxylase", "alternateName": "Retinoic Acid 4-Hydroxylase", "url": "https://questionsmedicales.fr/mesh/D000072516", "about": { "@type": "MedicalCondition", "name": "Retinoic acid 4-hydroxylase", "code": { "@type": "MedicalCode", "code": "D000072516", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.422.220.453.498.500" } } } ], "about": { "@type": "MedicalCondition", "name": "Famille-26 de cytochromes P450", "alternateName": "Cytochrome P450 Family 26", "code": { "@type": "MedicalCode", "code": "D000072500", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "David R Nelson", "url": "https://questionsmedicales.fr/author/David%20R%20Nelson", "affiliation": { "@type": "Organization", "name": "Department of Microbiology, Immunology and Biochemistry, University of Tennessee, Memphis, TN 38163, USA." } }, { "@type": "Person", "name": "F Peter Guengerich", "url": "https://questionsmedicales.fr/author/F%20Peter%20Guengerich", "affiliation": { "@type": "Organization", "name": "Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-0146. Electronic address: f.guengerich@vanderbilt.edu." } }, { "@type": "Person", "name": "Donghak Kim", "url": "https://questionsmedicales.fr/author/Donghak%20Kim", "affiliation": { "@type": "Organization", "name": "Department of Biological Sciences, Konkuk University, 120 Neungdongro, Gwangjjn-Gu, Seoul, 05025 Republic of Korea." } }, { "@type": "Person", "name": "Emily E Scott", "url": "https://questionsmedicales.fr/author/Emily%20E%20Scott", "affiliation": { "@type": "Organization", "name": "Program in Biophysics, University of Michigan, Ann Arbor, Michigan 48109; Departments of Medicinal Chemistry and Pharmacology, University of Michigan, Ann Arbor, Michigan 48109. Electronic address: scottee@umich.edu." } }, { "@type": "Person", "name": "Vitchan Kim", "url": "https://questionsmedicales.fr/author/Vitchan%20Kim", "affiliation": { "@type": "Organization", "name": "Department of Biological Sciences, Konkuk University, 120 Neungdongro, Gwangjjn-Gu, Seoul, 05025 Republic of Korea." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "The Self-Evaluation of Negative Symptoms in Differentiating Deficit Schizophrenia: The Comparison of Sensitivity and Specificity with Other Tools.", "datePublished": "2023-03-06", "url": "https://questionsmedicales.fr/article/36878191", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1159/000529244" } }, { "@type": "ScholarlyArticle", "name": "Rate control deficits during pinch grip and ankle dorsiflexion in early-stage Parkinson's disease.", "datePublished": "2023-03-03", "url": "https://questionsmedicales.fr/article/36867628", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1371/journal.pone.0282203" } }, { "@type": "ScholarlyArticle", "name": "Immersive virtual reality for improving cognitive deficits in children with ADHD: a systematic review and meta-analysis.", "datePublished": "2023-02-18", "url": "https://questionsmedicales.fr/article/36845650", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s10055-023-00768-1" } }, { "@type": "ScholarlyArticle", "name": "Association between olfactory dysfunction and mood disturbances with objective and subjective cognitive deficits in long-COVID.", "datePublished": "2023-02-02", "url": "https://questionsmedicales.fr/article/36818111", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fpsyg.2023.1076743" } }, { "@type": "ScholarlyArticle", "name": "Structural brain signatures of frailty, defined as accumulation of self-reported health deficits in older adults.", "datePublished": "2023-01-19", "url": "https://questionsmedicales.fr/article/36743441", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fnagi.2023.1065191" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Hémoprotéines", "item": "https://questionsmedicales.fr/mesh/D006420" }, { "@type": "ListItem", "position": 5, "name": "Cytochromes", "item": "https://questionsmedicales.fr/mesh/D003580" }, { "@type": "ListItem", "position": 6, "name": "Cytochrome P-450 enzyme system", "item": "https://questionsmedicales.fr/mesh/D003577" }, { "@type": "ListItem", "position": 7, "name": "Famille-26 de cytochromes P450", "item": "https://questionsmedicales.fr/mesh/D000072500" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Famille-26 de cytochromes P450 - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Famille-26 de cytochromes P450", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-17", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Famille-26 de cytochromes P450", "description": "Comment diagnostiquer une dysfonction des cytochromes P450 26 ?\nQuels tests sont utilisés pour évaluer l'activité des CYP26 ?\nLes symptômes cliniques aident-ils au diagnostic ?\nPeut-on utiliser l'imagerie pour le diagnostic ?\nLes antécédents médicaux sont-ils importants ?", "url": "https://questionsmedicales.fr/mesh/D000072500?mesh_terms=Attention+Deficit+and+Disruptive+Behavior+Disorders&page=1000#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Famille-26 de cytochromes P450", "description": "Quels sont les symptômes d'une anomalie des CYP26 ?\nLes anomalies des CYP26 causent-elles des douleurs ?\nY a-t-il des symptômes cutanés associés ?\nLes troubles de l'humeur sont-ils liés aux CYP26 ?\nLes anomalies des CYP26 affectent-elles la fertilité ?", "url": "https://questionsmedicales.fr/mesh/D000072500?mesh_terms=Attention+Deficit+and+Disruptive+Behavior+Disorders&page=1000#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Famille-26 de cytochromes P450", "description": "Comment prévenir les dysfonctionnements des CYP26 ?\nLes tests génétiques peuvent-ils prévenir des problèmes ?\nL'évitement de certains médicaments est-il conseillé ?\nLe suivi médical régulier est-il important ?\nLes habitudes de vie influencent-elles la santé des CYP26 ?", "url": "https://questionsmedicales.fr/mesh/D000072500?mesh_terms=Attention+Deficit+and+Disruptive+Behavior+Disorders&page=1000#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Famille-26 de cytochromes P450", "description": "Quels traitements sont disponibles pour les dysfonctionnements des CYP26 ?\nLes modifications alimentaires aident-elles ?\nDes médicaments spécifiques sont-ils utilisés ?\nLa thérapie génique est-elle une option ?\nLes traitements sont-ils personnalisés ?", "url": "https://questionsmedicales.fr/mesh/D000072500?mesh_terms=Attention+Deficit+and+Disruptive+Behavior+Disorders&page=1000#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Famille-26 de cytochromes P450", "description": "Quelles complications peuvent survenir avec les anomalies des CYP26 ?\nLes anomalies des CYP26 peuvent-elles causer des maladies chroniques ?\nY a-t-il un risque accru de cancer ?\nLes complications affectent-elles la qualité de vie ?\nLes complications sont-elles réversibles ?", "url": "https://questionsmedicales.fr/mesh/D000072500?mesh_terms=Attention+Deficit+and+Disruptive+Behavior+Disorders&page=1000#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Famille-26 de cytochromes P450", "description": "Quels sont les facteurs de risque pour les anomalies des CYP26 ?\nL'âge influence-t-il le risque ?\nLe mode de vie joue-t-il un rôle ?\nLes facteurs environnementaux sont-ils importants ?\nLes maladies préexistantes augmentent-elles le risque ?", "url": "https://questionsmedicales.fr/mesh/D000072500?mesh_terms=Attention+Deficit+and+Disruptive+Behavior+Disorders&page=1000#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une dysfonction des cytochromes P450 26 ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des tests génétiques et des analyses de sang peuvent aider à diagnostiquer les anomalies." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer l'activité des CYP26 ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests enzymatiques et des dosages de métabolites spécifiques sont utilisés." } }, { "@type": "Question", "name": "Les symptômes cliniques aident-ils au diagnostic ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des symptômes comme des troubles hormonaux peuvent indiquer une dysfonction." } }, { "@type": "Question", "name": "Peut-on utiliser l'imagerie pour le diagnostic ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "L'imagerie n'est pas couramment utilisée pour diagnostiquer les CYP26." } }, { "@type": "Question", "name": "Les antécédents médicaux sont-ils importants ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les antécédents de traitement médicamenteux peuvent influencer le diagnostic." } }, { "@type": "Question", "name": "Quels sont les symptômes d'une anomalie des CYP26 ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes incluent des troubles métaboliques et des déséquilibres hormonaux." } }, { "@type": "Question", "name": "Les anomalies des CYP26 causent-elles des douleurs ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent entraîner des douleurs liées à des déséquilibres hormonaux." } }, { "@type": "Question", "name": "Y a-t-il des symptômes cutanés associés ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des éruptions cutanées peuvent survenir en raison de déséquilibres métaboliques." } }, { "@type": "Question", "name": "Les troubles de l'humeur sont-ils liés aux CYP26 ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des troubles de l'humeur peuvent être liés à des déséquilibres hormonaux." } }, { "@type": "Question", "name": "Les anomalies des CYP26 affectent-elles la fertilité ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent affecter la fertilité en perturbant les niveaux hormonaux." } }, { "@type": "Question", "name": "Comment prévenir les dysfonctionnements des CYP26 ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation saine et un suivi médical régulier peuvent aider à prévenir." } }, { "@type": "Question", "name": "Les tests génétiques peuvent-ils prévenir des problèmes ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les tests génétiques peuvent identifier les risques avant l'apparition des symptômes." } }, { "@type": "Question", "name": "L'évitement de certains médicaments est-il conseillé ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, éviter les médicaments connus pour interférer avec les CYP26 peut être bénéfique." } }, { "@type": "Question", "name": "Le suivi médical régulier est-il important ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un suivi régulier permet de détecter précocement les anomalies." } }, { "@type": "Question", "name": "Les habitudes de vie influencent-elles la santé des CYP26 ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des habitudes de vie saines peuvent améliorer la fonction des CYP26." } }, { "@type": "Question", "name": "Quels traitements sont disponibles pour les dysfonctionnements des CYP26 ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent des thérapies hormonales et des ajustements médicamenteux." } }, { "@type": "Question", "name": "Les modifications alimentaires aident-elles ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une alimentation équilibrée peut soutenir le métabolisme hormonal." } }, { "@type": "Question", "name": "Des médicaments spécifiques sont-ils utilisés ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des médicaments ciblant les déséquilibres hormonaux peuvent être prescrits." } }, { "@type": "Question", "name": "La thérapie génique est-elle une option ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "La thérapie génique est encore en recherche pour traiter les anomalies des CYP26." } }, { "@type": "Question", "name": "Les traitements sont-ils personnalisés ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les traitements sont souvent adaptés en fonction des besoins individuels." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec les anomalies des CYP26 ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications incluent des troubles métaboliques graves et des déséquilibres hormonaux." } }, { "@type": "Question", "name": "Les anomalies des CYP26 peuvent-elles causer des maladies chroniques ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent contribuer à des maladies chroniques comme le diabète." } }, { "@type": "Question", "name": "Y a-t-il un risque accru de cancer ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Certaines anomalies peuvent augmenter le risque de cancers hormonodépendants." } }, { "@type": "Question", "name": "Les complications affectent-elles la qualité de vie ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les complications peuvent significativement altérer la qualité de vie." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être gérées, mais d'autres peuvent être irréversibles." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour les anomalies des CYP26 ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent des antécédents familiaux et l'exposition à certains médicaments." } }, { "@type": "Question", "name": "L'âge influence-t-il le risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le risque peut augmenter avec l'âge en raison de changements hormonaux." } }, { "@type": "Question", "name": "Le mode de vie joue-t-il un rôle ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un mode de vie malsain peut augmenter le risque de dysfonctionnement." } }, { "@type": "Question", "name": "Les facteurs environnementaux sont-ils importants ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exposition à des toxines environnementales peut affecter les CYP26." } }, { "@type": "Question", "name": "Les maladies préexistantes augmentent-elles le risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines maladies peuvent prédisposer à des anomalies des CYP26." } } ] } ] }

Sources (10000 au total)

The Self-Evaluation of Negative Symptoms in Differentiating Deficit Schizophrenia: The Comparison of Sensitivity and Specificity with Other Tools.

Psychometric properties of the Self-evaluation of Negative Symptoms (SNS) in subjects with the deficit subtype of schizophrenia (SCZ-D) have not been investigated so far. This study had the following ... Participants were 82 stable outpatients with schizophrenia, including 40 individuals with SCZ-D and 42 individuals with the non-deficit subtype (SCZ-ND).... Internal consistency was acceptable-to-good in both groups. Factor analysis revealed two dimensions (apathy and emotional). There were significant positive correlations of the SNS total score with the... The present findings indicate that the SNS has good psychometric properties in subjects with SCZ-D and those with SCZ-ND. Moreover, the SNS, the PANSS, and the SOFAS might be used as screening tools f...

Rate control deficits during pinch grip and ankle dorsiflexion in early-stage Parkinson's disease.

Much of our understanding of the deficits in force control in Parkinson's disease (PD) relies on findings in the upper extremity. Currently, there is a paucity of data pertaining to the effect of PD o... The purpose of this study was to concurrently evaluate upper- and lower-limb force control in early-stage PD and a group of age- and gender-matched healthy controls.... Twenty individuals with PD and twenty-one healthy older adults participated in this study. Participants performed two visually guided, submaximal (15% of maximum voluntary contractions) isometric forc... Compared with controls, PD demonstrated slower rates of force development and force relaxation during the foot task, and a slower rate of relaxation during the hand task. Force variability was similar... Together, these results provide quantitative evidence of an impaired capacity in PD to produce submaximal and rapid force across multiple effectors. Moreover, results suggest that force control defici...

Association between olfactory dysfunction and mood disturbances with objective and subjective cognitive deficits in long-COVID.

The coronavirus disease 2019 (COVID-19) has been associated with olfactory dysfunction. The persistent symptoms of anosmia or hyposmia were associated in previous studies with the development of memor... One hundred twenty-eight long-COVID participants were recruited. Reported symptomatology, subjective memory complaints, anxiety and depression symptomatology, and trait-anxiety were assessed. Subjecti... The subjective memory complaints and the anxiety and depression symptoms were similar among the groups, but the score in general cognitive function was lower in the participants with symptoms of acute... Olfactory dysfunction in the acute phase of the infection by COVID-19 is related to cognitive deficits in objective tests, and mood disturbances are associated with self-reported and objective memory....

Structural brain signatures of frailty, defined as accumulation of self-reported health deficits in older adults.

Frailty in older adults has been associated with reduced brain health. However, structural brain signatures of frailty remain understudied. Our aims were: (1) Explore associations between a frailty in... We designed a cross-sectional observational study from a population-based study (The Irish Longitudinal Study on Aging: TILDA). Participants aged ≥50 years who underwent the wave 3 MRI sub-study were ... In 523 participants (mean age 69, 49% men), lower cortex and thalamic volumes were independently associated with higher FI. Sensory and functional difficulties, diabetes, polypharmacy, knee pain, and ... The FI used had a recognizable but subtle structural brain signature in this sample. Only some FI deficits were directly associated with cortex volume, suggesting scope for developing FIs that include...

P50 sensory gating, cognitive deficits and depressive symptoms in first-episode antipsychotics-naïve schizophrenia.

Sensory gating P50 (SG-P50) may be involved in the pathophysiological mechanisms of impaired cognition in schizophrenia (SCZ). Comorbid depressive symptoms are common in SCZ patients and are also foun... We recruited 103 FEAN-SCZ patients (depression: n = 63; non-depression: n = 40) and 55 healthy controls. SG-P50 was measured using the standard auditory dual-click (S1&S2) paradigm. Clinical symptoms ... Compared with non-depressive patients, depressive patients had a significantly larger S2 amplitude (p = 0.005) and a higher S2/S1 ratio at trend level (p = 0.075) after corrected. There were significa... SG-P50 deficit may be an informational biomarker for depressive symptoms and neurocognitive impairments in FEAN-SCZ patients....

Association of cholesterol level with dopamine loss and motor deficits in Parkinson disease: A cross-sectional study.

Cholesterol is vital in neuronal function; however, the influence of cholesterol levels on parkinsonism is unclear. This study investigated the relationship between baseline total cholesterol (TC) lev... This cross-sectional study enrolled 447 drug-naïve patients with PD who underwent dopamine transporter (DAT) imaging. Multivariate linear regression was used to investigate the effect of cholesterol l... No significant correlation was found between TC levels and DAT availability after adjusting for potential confounders. Multivariate linear regression showed that TC levels were significantly and negat... This study suggests that TC levels affect parkinsonian motor symptoms, especially in subjects with low cholesterol status, whereas the severity of axial motor symptoms is negatively associated with TC...

Assessment of Bioenergetic Deficits in Patients With Parkinson Disease and Progressive Supranuclear Palsy Using 31P-MRSI.

Bioenergetic disturbance, mainly caused by mitochondrial dysfunction, is an established pathophysiological phenomenon in neurodegenerative movement disorders. The... In total, 30 PwPD, 16 PwPSP, and 25 healthy control subjects (HCs) underwent a clinical examination, structural magnetic resonance imaging, and... High-energy phosphate metabolites were remarkably decreased in PwPD, particularly in the basal ganglia (-42% compared with healthy controls and -43% compared with PwPSP, p<.0001). This result was not ... Our study shows that mitochondrial dysfunction and bioenergetic depletion contribute to idiopathic Parkinson's disease pathophysiology but not to progressive supranuclear palsy. Combined morphometric ...